The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023)
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciad032 ↗Kurz gefasst
Leitlinie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Mary K Hayden und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: COVID-19, Antigens, Viral, SARS-CoV-2, COVID-19 Serological Testing. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CDC HHS, HHS, Centers for Disease Control and Prevention.
Abstract (Originalsprache)
Immunoassays designed to detect SARS-CoV-2 protein antigens (Ag) are commonly used to diagnose COVID-19. The most widely used tests are lateral flow assays that generate results in approximately 15 minutes for diagnosis at the point-of-care. Higher throughput, laboratory-based SARS-CoV-2 Ag assays have also been developed. The number of commercially available SARS-CoV-2 Ag detection tests has increased rapidly, as has the COVID-19 diagnostic literature. The Infectious Diseases Society of America (IDSA) convened an expert panel to perform a systematic review of the literature and develop best-practice guidance related to SARS-CoV-2 Ag testing. This guideline is an update to the third in a series of frequently updated COVID-19 diagnostic guidelines developed by the IDSA. IDSA's goal was to develop evidence-based recommendations or suggestions that assist clinicians, clinical laboratories, patients, public health authorities, administrators, and policymakers in decisions related to the optimal use of SARS-CoV-2 Ag tests in both medical and nonmedical settings. A multidisciplinary panel of infectious diseases clinicians, clinical microbiologists, and experts in systematic literature review identified and prioritized clinical questions related to the use of SARS-CoV-2 Ag tests. A review of relevant, peer-reviewed published literature was conducted through 1 April 2022. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make testing recommendations. The panel made 10 diagnostic recommendations that address Ag testing in symptomatic and asymptomatic individuals and assess single versus repeat testing strategies. US Food and Drug Administration (FDA) SARS-CoV-2 Ag tests with Emergency Use Authorization (EUA) have high specificity and low to moderate sensitivity compared with nucleic acid amplification testing (NAAT). Ag test sensitivity is dependent on the presence or absence of symptoms and, in symptomatic patients, on timing of testing after symptom onset. In most cases, positive Ag results can be acted upon without confirmation. Results of point-of-care testing are comparable to those of laboratory-based testing, and observed or unobserved self-collection of specimens for testing yields similar results. Modeling suggests that repeat Ag testing increases sensitivity compared with testing once, but no empirical data were available to inform this question. Based on these observations, rapid RT-PCR or laboratory-based NAAT remain the testing methods of choice for diagnosing SARS-CoV-2 infection. However, when timely molecular testing is not readily available or is logistically infeasible, Ag testing helps identify individuals with SARS-CoV-2 infection. Data were insufficient to make a recommendation about the utility of Ag testing to guide release of patients with COVID-19 from isolation. The overall quality of available evidence supporting use of Ag testing was graded as very low to moderate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
- Department of Pathology, Rush University Medical Center, Chicago, Illinois, USA.
- Divisions of Infectious Diseases and Clinical Microbiology, University of Utah, Salt Lake City, Utah, USA.
- Department of Pediatrics, University of Washington, Seattle Children's Research Institute, Seattle, Washington, USA.
- Departments of Pathology and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Pathology and Clinical Microbiology Laboratory, Duke University School of Medicine, Durham, North Carolina, USA.
Förderung
- CDC HHS
- HHS
- Centers for Disease Control and Prevention
- Department of Health and Human Services
- NIH
Zitieren
APA
Hayden, M. K., Hanson, K. E., Englund, J. A., Lee, F., Lee, M. J., Loeb, M., Morgan, D. J., Patel, R., El Alayli, A., El Mikati, I. K., Sultan, S., Falck-Ytter, Y., Mansour, R., Amarin, J. Z., Morgan, R. L., Murad, M. H., Patel, P., Bhimraj, A., & Mustafa, R. A. (2024). The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad032
Vancouver
Hayden MK, Hanson KE, Englund JA, Lee F, Lee MJ, Loeb M, et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023). Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad032
BibTeX
@article{Hayden2024,
author = {Hayden, Mary K and Hanson, Kimberly E and Englund, Janet A and Lee, Francesca and Lee, Mark J and Loeb, Mark and Morgan, Daniel J and Patel, Robin and El Alayli, Abdallah and El Mikati, Ibrahim K and Sultan, Shahnaz and Falck-Ytter, Yngve and Mansour, Razan and Amarin, Justin Z and Morgan, Rebecca L and Murad, M Hassan and Patel, Payal and Bhimraj, Adarsh and Mustafa, Reem A},
title = {The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023)},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciad032}
}
EUVIMED